Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2023 Jul-Aug;20(4):14791641231188705.
doi: 10.1177/14791641231188705.

Mid-term safety and efficacy of magnesium bioresorbable vascular scaffolds - magmaris in diabetic population. 2-Years outcome in acute coronary syndrome cohort

Adrian Włodarczak  1   2 , Piotr Rola  1   3 , Mateusz Barycki  3 , Łukasz Furtan  3 , Magdalena Łanocha  4 , Szymon Włodarczak  2 , Marek Szudrowicz  2 , Jan Jakub Kulczycki  2 , Joanna Jaroszewska-Pozorska  2 , Michalina Kędzierska  5 , Katarzyna Giniewicz  6 , Adrian Doroszko  7 , Maciej Lesiak  8
Affiliations
Multicenter Study

Mid-term safety and efficacy of magnesium bioresorbable vascular scaffolds - magmaris in diabetic population. 2-Years outcome in acute coronary syndrome cohort

Adrian Włodarczak et al. Diab Vasc Dis Res. 2023 Jul-Aug.

Abstract

Background: Diabetes type 2 is one of the strongest risk factors affecting coronary artery disease (CAD) and is also a marker of poor short and long-term prognosis in subjects with acute coronary syndrome (ACS) treated with percutaneous coronary intervention (PCI) with subsequent drug-eluting stent (DES) implantation. Chronic local vascular inflammation along with endothelial dysfunction is postulated to be the pathophysiological background of unfavorable results. The second generation of metallic magnesium BRS -Magmaris (Biotronik, Berlin, Germany) had been introduced to clinical practice to overcome these limitations.

Methods: We evaluated 2-years clinical outcomes after Magmaris BRS implantation in NSTE-ACS diabetic (n-72) and non-diabetic (n-121) cohorts.

Results: No significant differences between diabetic and non-diabetes cohorts were noticed in terms of Primary Outcome (cardiac death, myocardial infarction, stent thrombosis) (8.1% vs 3.3% p = 0.182) and Principal secondary outcome - TLF- target lesion failure (9.5% vs 3.3% p = 0.106) at 2-years follow-up.

Conclusions: 2-years outcome suggests good safety and efficacy of the magnesium BRS (Magmaris) in NSTE- ACS and concomitant DM. Nevertheless, there is a strong need for large multicenter, randomized, prospective studies for a full assessment of this novel device in diabetic patients with ACS.

Keywords: Diabetes mellitus (DM); acute coronary syndrome (ACS); bioresorbable materials; coronary artery disease (CAD); magmaris; magnesium bioresorbable scaffold (BRS); mid-term outcome; percutaneous coronary intervention (PCI).

PubMed Disclaimer

Conflict of interest statement

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Figures

Figure 1.
Figure 1.
A flow chart of the study design.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Arnold SV, Bhatt DL, Barsness GW, et al.American Heart Association Council on Lifestyle and Cardiometabolic Health and Council on Clinical Cardiology. Clinical Management of Stable Coronary Artery Disease in Patients With Type 2 Diabetes Mellitus: A Scientific Statement From the American Heart Association. Circulation 2020; 141: e779–e806. - PubMed
    1. Naito R, Miyauchi K. Coronary Artery Disease and Type 2 Diabetes Mellitus. Int Heart J 2017; 58: 475–480. - PubMed
    1. Goyal SN, Bharti S, Krishnamurthy B, et al.Impact of metabolic syndrome on re-stenosis development: role of drug-eluting stents. Diab Vasc Dis Res 2012; 9: 177–188. - PubMed
    1. Giustino G, Colombo A, Camaj A, et al.Coronary In-Stent Restenosis: JACC State-of-the-Art Review. J Am Coll Cardiol 2022; 80: 348–372. - PubMed
    1. Jakubiak GK, Pawlas N, Cieślar G, et al.Pathogenesis and Clinical Significance of In-Stent Restenosis in Patients with Diabetes. Int J Environ Res Public Health 2021; 18: 11970. - PMC - PubMed

Publication types